Novartis Ag (NVS) Interest Expenses (2009 - 2026)
Novartis Ag (NVS) posted Interest Expenses of $462.0 million for Q2 2026, up 234.69% sequentially from -$343.0 million in Q1 2026, and up 59.86% YoY from $289.0 million in Q2 2025.
Novartis Ag (NVS) Interest Expenses (2009 - 2026) Analysis & Trends
Novartis Ag has reported Interest Expenses for 18 years, with the latest figure at $462.0 million in Q2 2026.
- Quarterly Interest Expenses rose 59.86% year-over-year to $462.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$475.0 million (up 51.33% YoY) and the FY2025 annual result came in at $1.1 billion, up 13.72% from the prior year.
- Interest Expenses rose to $462.0 million in Q2 2026 per NVS's latest filing, from -$343.0 million in the prior quarter.
- Over five years, Interest Expenses peaked at $462.0 million in Q2 2026 and troughed at -$731.0 million in Q4 2024.
- A 5-year average of -$220.3 million and a median of -$238.5 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 213.84% in 2024, then soared 213.33% in 2025.
- Over 5 years, Interest Expenses stood at -$593.0 million in 2022, then slipped by 7.59% to -$638.0 million in 2023, then decreased by 14.58% to -$731.0 million in 2024, then surged by 58.41% to -$304.0 million in 2025, then soared by 251.97% to $462.0 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $462.0 million, -$343.0 million, and -$304.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 462.00 Mn |
| Jun 30, 2026 | 462.00 Mn |
| Mar 31, 2026 | -343.00 Mn |
| Mar 31, 2026 | -343.00 Mn |
| Dec 31, 2025 | -304.00 Mn |
| Dec 31, 2025 | -304.00 Mn |
| Sep 30, 2025 | -290.00 Mn |
| Sep 30, 2025 | -290.00 Mn |
| Jun 30, 2025 | 289.00 Mn |
| Jun 30, 2025 | 289.00 Mn |
| Mar 31, 2025 | -270.00 Mn |
| Mar 31, 2025 | -270.00 Mn |
| Dec 31, 2024 | -731.00 Mn |
| Dec 31, 2024 | -731.00 Mn |
| Sep 30, 2024 | -264.00 Mn |
| Sep 30, 2024 | -264.00 Mn |
| Jun 30, 2024 | -255.00 Mn |
| Jun 30, 2024 | -255.00 Mn |
| Mar 31, 2024 | -221.00 Mn |
| Mar 31, 2024 | -221.00 Mn |